Cargando…

Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

PURPOSE: The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [(89)Zr]Zr-DFO-girentuximab-PET/CT and [(18)F]FDG-PET/CT in detecting ccRCC lesions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verhoeff, Sarah R., van Es, Suzanne C., Boon, Eline, van Helden, Erik, Angus, Lindsay, Elias, Sjoerd G., Oosting, Sjoukje F., Aarntzen, Erik H., Brouwers, Adrienne H., Kwee, Thomas C., Heskamp, Sandra, Hoekstra, Otto S., Verheul, Henk, van der Veldt, Astrid A. M., de Vries, Elisabeth G. E., Boerman, Otto C., van der Graaf, Winette T. A., Oyen, Wim J. G., van Herpen, Carla M. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647180/ https://www.ncbi.nlm.nih.gov/pubmed/31172212 http://dx.doi.org/10.1007/s00259-019-04358-9

Ejemplares similares

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2023)

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET”
por: Raavé, René, et al.
Publicado: (2019)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET
por: Chomet, Marion, et al.
Publicado: (2020)

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2021)

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2022)

Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with (111)In-girentuximab
por: van Oostenbrugge, Tim J., et al.
Publicado: (2019)

Click-to-Release: Cleavable Radioimmunoimaging with [(89)Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
por: Vlastara, Maria, et al.
Publicado: (2023)

In Vivo PET Imaging of Monocytes Labeled with [(89)Zr]Zr-PLGA-NH(2) Nanoparticles in Tumor and Staphylococcus aureus Infection Models
por: Krekorian, Massis, et al.
Publicado: (2021)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for (89)Zr-immuno-PET
por: Vugts, Danielle J., et al.
Publicado: (2016)

Comparative biodistribution analysis across four different (89)Zr-monoclonal antibody tracers—The first step towards an imaging warehouse
por: Bensch, Frederike, et al.
Publicado: (2018)

Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC
por: Oosterwijk-Wakka, Jeannette C., et al.
Publicado: (2015)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

Phase I study to assess safety, biodistribution and radiation dosimetry for (89)Zr-girentuximab in patients with renal cell carcinoma
por: Merkx, Robin I. J., et al.
Publicado: (2021)

Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of (89)Zr Immune-PET Tracers
por: Imura, Ryota, et al.
Publicado: (2021)

Application of (89)Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
por: Stergiou, N., et al.
Publicado: (2023)

(89)Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas
por: Herrero Alvarez, Natalia, et al.
Publicado: (2023)

Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
por: Jauw, Yvonne W. S., et al.
Publicado: (2019)

Biodistribution PET/CT Study of Hemoglobin-DFO-(89)Zr Complex in Healthy and Lung Tumor-Bearing Mice
por: Kiraga, Łukasz, et al.
Publicado: (2020)

The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and In vivo Performance of (89)Zr-DFO-Pertuzumab
por: Vivier, Delphine, et al.
Publicado: (2020)

Feasibility of real-time in vivo (89)Zr-DFO-labeled CAR T-cell trafficking using PET imaging
por: Lee, Suk Hyun, et al.
Publicado: (2020)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

Therapeutic Response Monitoring with (89)Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
por: Kang, Minwoo, et al.
Publicado: (2022)

Biodistribution of (89)Zr-DFO-labeled avian pathogenic Escherichia coli outer membrane vesicles by PET imaging in chickens
por: Li, Zhe, et al.
Publicado: (2022)

Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [(89)Zr]Zr-DFO-PEG(5)-Tz
por: Lumen, Dave, et al.
Publicado: (2022)

Metal Coordination Properties of a Chromophoric Desferrioxamine (DFO) Derivative: Insight on the Coordination Stoichiometry and Thermodynamic Stability of Zr(4+) Complexes
por: Savastano, Matteo, et al.
Publicado: (2021)

Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients
por: Heskamp, Sandra, et al.
Publicado: (2015)

Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo
por: Basaco, Tais, et al.
Publicado: (2018)

Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using (89)Zr-DFO-Trastuzumab
por: Holland, Jason P., et al.
Publicado: (2010)

(89)Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
por: van Brummelen, Emilie M.J., et al.
Publicado: (2018)

Preclinical PET imaging with the novel human antibody (89)Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues
por: Kelly, Marcus P, et al.
Publicado: (2021)

Immuno-PET Imaging to Assess Target Engagement: Experience from (89)Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
por: Menke-van der Houven van Oordt, C. Willemien, et al.
Publicado: (2019)

A study of the $^{90}Zr(p,t)^{88}Zr$ reaction
por: Guazzoni, P, et al.
Publicado: (1997)

Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using ((89)Zr)-DFO- Galectin3-F(ab')(2) mAb
por: Varasteh, Zohreh, et al.
Publicado: (2021)

Mesenchymal Stem Cells Do Not Lose Direct Labels Including Iron Oxide Nanoparticles and DFO-(89)Zr Chelates through Secretion of Extracellular Vesicles
por: Gao, Yue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2pb48oh3erguarpu66pjohfic5